This study looks at the long-term safety and effectiveness of gene-modified T-cell therapy. It involves both children and adults who have received this treatment in earlier studies. The goal is to understand how well the therapy works and any effects it may have over time.
The trial's ID number is NCT03435796. It is in Phase 2 and Phase 3, which means it is studying how well the treatment works and how safe it is. This trial is regulated by the FDA and aims to include about 1541 participants.
Who can join
Anyone who is a child, adult, or older adult can join if they have received at least one infusion of gene-modified T cells in a previous study. Participants must also sign a consent form. There are no specific exclusions noted, but the trial team will confirm eligibility.
Condition
Neoplasms
Age group
All ages
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be followed for long-term outcomes after receiving gene-modified T cell therapy in earlier studies. No new treatments will be given in this trial. Everyone will be part of one group, and their health will be monitored over time.
Where
This trial is enrolling at 100 locations. Recruiting sites are listed first.
Banner MD Anderson Cancer Center
Gilbert, Arizona
Recruiting
Baptist Cancer Center
Miami, Florida
Recruiting
Cancer Center of Kansas
Wichita, Kansas
Recruiting
Children's Hospital of Philadelphia-Center for Childhood Cancer Research
Philadelphia, Pennsylvania
Recruiting
City Of Hope
Duarte, California
Recruiting
Cleveland Clinic Foundation
Cleveland, Ohio
Recruiting
Colorado Blood Cancer Institute
Denver, Colorado
Recruiting
Columbia University Medical Center/New York-Presbyterian Hospital
New York, New York
Recruiting
Study contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com